Business
Helix BioPharma Corp. announces fiscal 2007 results
Helix BioPharma Corp. announces fiscal 2007 results.
About this update from Helix Biopharma Corp.
[{"type":"text","content":"\n\n\n\nWKN: 918 846\n\n\nAURORA, ON, Oct. 26 /CNW/ - Helix BioPharma Corp. (TSX, FSE: "HBP") today\nannounced financial results for the year ended July 31, 2007.\n\n\nDuring the 2007 fiscal year, the Company continued to make progress with\nits clinical (Topical Interferon Alpha-2b) and pre-clinical (L-DOS47)\ndevelopment programs. The following are selected highlights during the 2007\nfiscal year and subsequent to year-end.\n\n\nHIGHLIGHTS\n\n- Topical Interferon Alpha-2b\n\n - Announced positive Phase II clinical results with Topical\n Interferon Alpha-2b in patients with HPV-induced low-grade\n squamous intraepithelial lesions ("LSIL")\n\n - Initiated enrollment in Phase II clinical trial with Topical\n Interferon Alpha-2b in patients with HPV-induced ano-genital warts\n\n- L-DOS47\n\n - Awarded two U.S. patents for DOS47, a broad anti-cancer\n therapeutic candidate\n\n - Presented L-DOS47 findings at the fourth international conference\n on "Tumour Microenvironment" in Florence, Italy\n\n - Presented L-DOS47 findings at Keystone Symposia meeting,\n "Antibodies as Drugs: From Basic Biology to Clinic"\n\n - Signed L-DOS47 manufacturing agreement with BioVectra DCL\n\n- Financing\n\n - Completed a private placement financing on October 11, 2006 for\n gross proceeds of $7,044,500.\n\n- Other\n\n - Shareholders approved management proposals and elected\n management's slate of directors at the 2007 annual meeting of\n shareholders, following a proxy dispute\n\n - Announced University of Arizona Professor, Kenneth D. Hatch,M.D.,\n as medical advisor\n\n - Mr. Jerome F. McElroy resigned as Chairman and Director of the\n Company\n\n - Introduced a new company logo as part of our ongoing efforts to\n renew our market image\n\n\nFor the fiscal year ended 2007, the Company recorded a net loss of\n$7,674,000, which represents an increase of $735,000 when compared to fiscal\n2006. In fiscal 2006, the Company recorded a net loss of $6,939,000 and is\nlower by $686,000 when compared to fiscal 2005. The net loss per common share\nfor the fiscal year ended 2007 was $0.22 and remained unchanged when compared\nto fiscal 2006. Fiscal 2006's net loss per share was lower by $0.06 when\ncompared to the loss per common share for fiscal 2005.\n\n\nProduct revenue, license fees and royalties as well as research...